CN102533983A - Horizontal in-situ hybridization detection kit and detection method as well as application for MICRORNA-330 in earlier stage of cancer pathologic evolution - Google Patents

Abstract

The invention discloses an in-situ hybridization detection kit which comprises a hybridization probe and a marker. The invention also discloses an in-situ hybridization detection method for microRNA-330 being closely related to the early pathologic evolution of various cancers by using the kit. The in-situ hybridization detection method comprises the following steps of: (1) under the condition that the hybridization probe and a target sequence can form a stable hybridization complex, leading RNA (Ribonucleic Acid) to be tested in a substrate to be in contact with the hybridization probe, and forming a hybridization complex; and (2) detecting the hybridization complex. The kit and the detection method provided by the invention can be used for detecting the expression quantity of the microRNA-330 at the level of RNA, which is more early obtained in comparison with detection indexes of imaging medicine and the traditional clinical biochemistry, thereby the RNA level screening can be realized truly in the earlier stage of canceration, and simultaneously, the detection method is simple and convenient and low in cost and is convenient to popularize and apply in county and district-level hospitals.

Description

Cancer pathology develops the horizontal hybridization in situ detection kit of MICRORNA-330 and detection method and application in earlier stage

Technical field

The present invention relates to field of biological detection, more particularly, relate to develop the correlation detection technology that rna expression changes (pathology evolution process) with various cancer pathology.

Background technology

According to the data that domestic and international authoritative institution provides, the newly-increased number 2,600,000 of the annual cancer of China, death toll nearly 2,100,000; The patient more than 700 ten thousand; The annual newly-increased cancer patients 8,000,000 in the whole world, death toll is near 8,000,000, and the patient has more than 8,400 ten thousand people approximately; To double to the above number of the year two thousand twenty, this is one group of fearful numeral.Cancer diagnosis and treatment cost is increasingly high; (poor area maybe be higher by cancer patients's year medical expense 200,000; Developed regions possibly exceed 200,000 far away), more than 700 ten thousand patients, annual cost is 1.4 trillion Renminbi; Deduction cost 35% is about 400,000,000,000, has every year 1000000000000 Renminbi to consume in vain approximately.And the cancer patients is most of can be dead soon after treatment.Therefore, existing clinical cancer diagnosis and treatment pattern must change, and innovative point of the present invention is to accomplish preventative examination in advance, in time gets involved preventative regulation and control and prophylactic treatment then, accomplishes preventiveing treatment of disease of gene level cancer.

An annual report has been done by eight tame units such as U.S. sanitary research institute in 2005, cancer research institute, Disease Control and Prevention Center; Anticancer Great War to initiation in 1972 is looked back; Report thinks that the mankind are failures in anticancer Great War; Conclusion is that cancer mortality does not reduce, and it is enumerated out and causes the Several Factors of anticancer Great War failure to be: 1. tumour cell heterogeneous (polymorphum); 2. tumor cell drug resistance; 3. cancer therapy drug mentality of designing imperfection (animal model designs not science) etc.Simultaneously, also propose to examine closely again the measure of existing diagnosis and treatment cancer in this report.

The inventor is in the middle discovery that studies for a long period of time, and the major reason that causes cancer mortality not fallen is to accomplish real early diagnosis.Come diagnosing cancer according to existing clinical medicine image (B ultrasonic, CT, zeugmatography etc.) and with other biochemistry (cancer antigen, CEACAMS, carbohydrate hormone, the cytolemma factor, the nucleus factor, cell streaming technology) index; All be that tumour forms the back diagnosis; The former will learn in a organized way and change or existing occupying lesion, latter's major part be tumour form the back secreted, discharge or the affinity tag of tumour.The clinical idea of tradition thinks that occupancy cancer piece is the diagnosis that belongs to early-stage cancer under 2 centimeters; This notion is worth conscientiously discussing, and it is rigorous inadequately that 2 centimeters early stage these of following cancer piece genus define science, analyzes from the cytology angle; 1 centimeter lump has 100,000,000 tumour cells approximately; Its three-dimensional cell stack number of 2 centimeters lump is far above 200,000,000 tumour cells, produces from canceration early stage to the mono-clonal cancer cells and forms 2 centimeters cancer piece, and its pathology evolution process is quite long; Possibly be (except the special case) more than 5 years or 10 years or even 10 years; What be difficult to confirm is in this pathology evolution process, and lump is unique spot of cancer and independent focus, and possible cancer cells is moved to other tissue or organ growth already.Clinical study confirms already, in case when forming lump, other cancer cells is moved to other position clonal growth through different approaches, in case behind the excision primary tumor, other organ recurrent foci or multiple cancer piece kitchen range successively form.Therefore; Whether define in early days with the cancerous swelling piece size below 2 centimeters clinically, rigorous inadequately (some case is when finding primary lesion; Find metastatic lesion simultaneously; Not in the content of our statement), at this moment be diagnosis in late period and treatment of late stage in fact, this is the true cause that causes cancer mortality not fallen.

Along with molecular biotechnology is perfect day by day, functional genomics, the deep expansion of research such as cancer genomics in order to seek more early stage diagnosing cancer, treatment cancer and preventing cancer, makes great progress.So far, we might do more accurate early screening and diagnosis on the one-level functional transcription product (mRNA level or microRNA) of gene, preceding in canceration early stage or cancer cells formation (mono-clonal), just can accomplish early prediction and examination.The present invention adopts the nucleic acid hybridization in situ technology, selects many group clinical samples (cancer patient, high risk population, normal control), and check and analysis are carried out in the early warning of MICRORNA-330 gene and various cancers.

Small ribonucleic (microRNA/miRNA) is the few ribonucleic molecule that a segment length is about 22 nucleotides, and they can suppress translation or cause the degraded of mRNA to reduce the performance of gene by regulation and control mRNA.Many discovering arranged recently, and miRNA and cancer have the dependency of height.Therefore inference miRNA possibly be of cancerization process lead because of.Up to the present; On human body, there are 700 miRNA of surpassing to come to light; And nearly about 100 miRNA is identified with human cancer and has dependency, and this wherein includes kinds of tumors such as breast cancer, leukemia, lung cancer, the cancer of the brain, liver cancer, carcinoma of the colon and rectum, glioma, pituitary tumor.Discover that microRNA-330 is relevant with the prostate cancer morbidity, the key player who in prostate cancer pathology evolution process, plays the part of.Discover that expression amount and the normal prostatic cell strain of miR-330 in the prostate cancer cell strain make comparisons, the phenomenon of obvious decline is arranged.Further, utilize bioinformatics method and luciferase reporter assay, we find that the regulation protein of miR-330 is E2F1.Analyze in prostate cancer cell strain and the prostate cancer clinical tissue, the E2F1 protein expression, the proteic expression of discovery E2F1 really with the expression of miR-330, opposite tendency is arranged.Change in order to understand the regulation and control machine of miR-330 in cell; Transition performance miR-330 in the prostate cancer cell strain; The result finds that miR-330 can suppress the phosphorylation of Akt indirectly by the performance that suppresses E2F1, and impels the growth of cell to be suppressed, and then cell death inducing.Research shows microRNA-330 low expression in lung cancer and other cancer, and it is a kind of microRNA of cancer suppressing function.The inventor finds that under study for action microRNA-330 has the obvious expression quantitative changeization various cancer patientss (particularly lung cancer, prostate cancer), cancer high risk population, normal control people, and microRNA-330 is become as the various cancers of early screening has very important clinical diagnosis meaning early stage.MICRORNA-330 becomes low expression the in early stage (particularly lung cancer, prostate cancer) and the canceration process in various cancers.He do in examination in canceration early stage, and various cancer therapy after recurrence, shift early warning very important clinical meaning also arranged.

The contriver is in long term studies; Drawn a kind of new concept, the clinical diagnosis and treatment pattern of cancer and other clinical major disease must change, and can not only stop present treating the disease affected (morbidity back diagnosis and treatment); Accomplish preventative diagnosis and treatment; Accomplish treating the disease affected, only in this way could reduce the M & M of major disease, reduce social cost and medical treatment cost.Therefore, the contriver innovates theoretical and technical in the rna level kit for screening and medicine of exploitation and production major disease.Particularly screen clinical samples (normal population, cancer high risk population, tumour patient); Broken through healthy tissues and tumor tissues consistency research and development thinking relatively, sought and developed the rna level that becomes before the cancer, developed closely related with cancer early gene physiopathology; And the extremely important target of clinical meaning; Tumour is clinically formed the preventative diagnosis and treatment that diagnosis and treatment pattern in back becomes tumour, striven for the time and the space of tumor diagnosis and treatment, reach preventing cancer.

At present the high flux gene chip analytical technology is all adopted in the research of MICRORNA-330; And these methods are used for the scientific research aspect more; The incompatibility clinical application; And detect RNA than genetic analysis science (the DNA analysis major part is on the presentation of susceptibility, and mRNA is functional embodiment) more, than analysis of protein more reliable (mRNA and albumen are transcribed sometimes asynchronous).Detection technique and test kit according to existing literature data MicroRNA-330 level do not appear in the newspapers.

The inventor is in the requirement to the novelty invention; Designed (cancer patients, high risk population, normal women's contrast) different pieces of information example group; Detect with hybridization in situ technique; The result shows that above cancer patient MICRORNA-330 is low and expresses, and the high risk population has and expresses 16-28% in various degree, and normal control all is a high expression level.Show that the various cancers of MICRORNA-330 become the important symbol thing of examination in early stage.

Hybridization in situ technique (in situ hybridization) combines molecular biology and cytochemistry technology, is probe with the nucleic acid molecule of mark, in the technology of histocyte in situ detection specific nucleic acid molecule.Its principle is to make the nucleic acid strand (being probe) that contains distinguished sequence, process mark; Under optimum conditions with histocyte in the complementary nucleic acid strand be that target nucleic acid is hybridized; With radioautograph or immunocytochemistry label probe is surveyed again, thereby shown special DNA or RNA molecule at cell in-situ.

The probe of in situ hybridization is molecule or sequence the unknown but the known nucleic acid molecule of molecule (though indeterminate this molecule full sequence of known array; But what target molecule known its is directed against), the kind of probe can be divided into dna probe, cDNA probe, cRNA probe and synthetic oligonucleotide probe again by the properties of nucleic acids difference.For the ease of spike, probe must be used certain means mark in addition, is beneficial to later detection.Affinity tag commonly used comprises radionuclide and non-radioactive marker's two big classes.Isotopic label commonly used has³H,³⁵S,¹²⁵I with³²P.Advantages such as susceptibility is high though isotopic label has, the back of the body end is comparatively clear because ri all can damage human and environment, have by the substituted trend of heterotope recently.At present the most frequently used in the heterotope affinity tag have three kinds of vitamin H, digoxin and resorcinolphthaleins.The method that detects these affinity tags all is a sensitive extremely.

According to used probe and to detect nucleic acid difference can be divided into DNA-DNA again, RNA-DNA, RNA-RNA hybridization.No matter but the hybridization of any form, all must be through five big processes, promptly histiocytic fixing, prehybridization, hybridization, flushing and demonstration.The present invention adopts the hybridization mode of RNA-RNA; Synthetic probe (RNA) and the target RNA that detects are the principles that adopts base complementrity (hybridization is complementary); Simultaneously through long-time research with observe the contrast of miRNA chip of expression spectrum, start and termination place the result not influence of residue to detecting.

In view of the diagnosis of cancer clinically (medical imaging and biochemical indicator thing all are the diagnosis after tumour forms) at present is the diagnosis in late period, treatment also is a treatment of late stage, the treatment pattern that causes mortality ratio not fallen.Original intention of the present invention is to want to change at present the diagnosis and treatment pattern of major disease clinically; Become preventative preventiveing treatment of disease from treating the disease affected; Reach preventative diagnosis and treatment; Present medical imaging means and numerous biochemical marker can't be detected become rna level before the cancer and quantize changes technology, do the technological breakthrough of novelty, provide that to become the rna level examination before the cancer technological.Making has had a preceding technology that becomes the real early screening of rna level of new cancer clinically, for the diagnosis and treatment of clinical cancer are raced against time and the space.

Summary of the invention

The object of the invention at first provides a kind of hybridization in situ detection kit, and it comprises in situ hybridization detection probes and affinity tag.

Secondly, the present invention also will provide the mentioned reagent box to be used for various canceration examinations in early stage and art recurrence, to shift the relevant in situ hybridization detection method of early warning.

For realizing the object of the invention; Technical scheme of the present invention is following: the present invention at first provides a kind of hybridization in situ detection kit, and it comprises hybridization probe and affinity tag, wherein; Described hybridization probe is the complementary sequence of sequence shown in the sequence table SEQ ID NO.1; Sequence number: NR_029886, MICRORNA-330 consecutive nucleotides sequence length is 94bp, is positioned at karyomit(e) 19q13.32 " on.

A preferred version of test kit of the present invention is that described affinity tag is selected from radioactive substance, chemoluminescence or substance that show color, vitamin H, metal king crab, resorcinolphthalein, enzyme and nano material.

A preferred version of test kit of the present invention is also to comprise hybridization solution.

A preferred version of test kit of the present invention is also to comprise toughener.

A preferred version of test kit of the present invention is also to comprise developer.

Canceration MICRORNA-330 kit for screening in early stage using value of the present invention is that the examination in early stage to various canceration early stage examination, especially prostate cancers, lung cancer reaches cancer postoperative recurrence, transfer, diffusion generation early warning, further cooperates clinical treatment.

The present invention also provides a kind of detection method of MICRORNA-330 in situ hybridization, may further comprise the steps:

(1) described in the above hybridization probe and target sequence can form under the condition of stablizing hybridization complex, and RNA to be measured in the substrate is contacted with hybridization probe, form hybridization complex; With

(2) detect said hybridization complex.

Detection method of the present invention, wherein preferably, the described condition of stablizing hybridization complex that forms is: the temperature of nucleic acid hybridization is 42 ℃; The time of nucleic acid hybridization is 16-24 hour.

Detection method of the present invention, wherein preferably, described substrate is selected people's blood leucocyte sample or other organ-tissue cell specimen for use.More preferably be that described blood preparation or other organ-tissue cell specimen are from various cancer patientss, various cancer high risk population, healthy normal population.

Detection method of the present invention, wherein preferably, described cancer high risk population, cancer build up a family fortune well family, various cancer patients (particularly lung cancer, prostate cancer).

Detection kit of the present invention is to adopt nucleic acid hybridization technique and groupization immunization method to combine; With MICRORNA-330 is detected object; Synthesising probing needle is the complementary sequence of MICRORNA-330 sequence, and the substrate of detection is the expression amount of blood of human body sample white corpuscle or histiocytic RNA.The display packing of hybridization in situ technique can provide sxemiquantitative or the quantitative expression deciding degree of MICRORNA-330.Judge the expression amount of above RNA according to the immunohistochemical methods colour developing of hybridization back; Normal people MICRORNA-330 high expression level; Promptly a large amount of colour developings, MICRORNA-330 expresses in the low expression of cancer patient or zero, and the high risk population has a certain amount of little 14-28%; With the normal control crowd apparent difference is arranged relatively, this expression of gene amount is all lower than normal people expression amount.

The component of diagnostic kit of the present invention is by hybridization probe, hybridization solution, developer, compositions such as synergistic agent.The nucleic acid hybridization principle of this test kit is that the molecular biology insider all knows, and the concrete operations step is to carry out quantitative analysis, result's report under sample disposal, prehybridization, hybridization, immunohistochemical staining, the mirror, and wherein the concrete steps of hybridization comprise:

1). sample to be measured is put into reactive tank;

2). instrument discards liquid automatically, adds Digestive system automatically;

3). instrument discards liquid automatically, and the back is fixing automatically;

4). instrument discards liquid automatically, automatically prehybridization (42 ℃);

5). instrument discards liquid automatically, cleans automatically;

6). instrument discards liquid automatically, automatically hybridization (42 ℃);

7). instrument discards liquid automatically, cleans automatically;

8). instrument discards liquid automatically, and automatic and DIG antibody is cultivated (room temperature);

9). instrument discards liquid automatically, cleans colour developing automatically;

10). take out the mounting microscopy.

The scheme of a preferred embodiment of the present invention is: with MICRORNA-330 synthetic nucleic probe with digoxigenin labeled (cDNA of digoxigenin labeled, RNA and oligonucleotide probe; Not only probe has a biotin labeling advantage; Also having overcome biotin labeled probe is organized the endogenous vitamin H to do shortcomings such as sorrow in the crossover process in position); This hybridization probe and the leukocytic RNA nucleic acid to be measured of blood of human body are hybridized,, under light microscopic, observe existence and the location of RNA again with the method colour developing of immunohistochemical methods; According to painted cell count, judge the expression amount of purpose RNA.

The inventive method is a nucleic acid hybridization in situ technology commonly used at present; This method is through detecting the MICRORNA-330 expression amount in the substrate cell; Be used for confirming that various cancer pathology develop the RNA variable quantity in early stage (particularly lung cancer, prostate cancer), the various cancerations of early warning (lung cancer, prostate cancer) whether take place and various cancer patients treatment after the prediction of whether recurring, shifting.Because MICRORNA-330 is high expression level in the normal people, if the MICRORNA-330 expression amount reduces, the risk of suffering from cancer be described, explain that canceration takes place, or the cancer patient postoperative recurs, shifts, thus the diagnostic message of acquisition cancer.A test kit can many person-portions use or person-portion use.

The present invention has following beneficial effect: clinical meaning of the present invention is the more early stage variation that detects MICRORNA-330 expression amount in various cancerations (special lung cancer, prostate cancer) generation and the pathology evolution process of following the tracks of, and the various cancers of early warning take place, development trend.Diagnostic kit of the present invention and other detection and cancer markers clinically, and the medical imaging inspection has apparent difference.The present invention can detect the MICRORNA-330 unconventionality expression at rna level; Before the recurrence of occupancy carninomatosis kitchen range is not found in the medical imaging inspection; Before the cancer biochemical indicator does not produce unusually; Also do not form before the tumour, can accomplish the information acquisition of above abnormal gene expression early, predict for real early warning of clinical carninomatosis patient and treatment back transfer and relapse early.So just might implement early screening, early prevention, the early treatment of cancer, might from the source, thoroughly effect a radical cure various cancer foul diseases.

In addition, characteristics highly sensitive, high specificity that test kit provided by the invention has, simultaneously, detection method of the present invention is convenient and simple for operation, can be widely used and promoted in Municipal Hospitals.

Description of drawings

Fig. 1 is a MICRORNA-330 hybridization in situ technique schema of the present invention.

Fig. 2 is that lung cancer patient MICRORNA-330 expresses the reduction picture in the embodiment of the invention.

Fig. 3 is that high risk population MICRORNA-330 expresses picture in the embodiment of the invention.

Fig. 4 is that normal people MICRORNA-330 expresses picture in the embodiment of the invention.

Embodiment

Below in conjunction with embodiment, content of the present invention is described more specifically.Should be appreciated that following embodiment is used for explanation and non-limiting content of the present invention, any pro forma change or accommodation will fall into protection scope of the present invention.

Embodiment 1

Prepare the in situ hybridization test kit of present embodiment according to ordinary method, this test kit comprises that wherein: the probe mark thing of present embodiment is selected digoxin for use with hybridization probe, affinity tag, the specification sheets of MICRORNA-330 design.

The test kit hybridization solution is formed:

Digestive system	100 μ L/pipe	1 pipe/box	Colourless transparent liquid
				Protection liquid	100 μ L/pipe	1 pipe/box	Colourless transparent liquid
Prehybridization solution	1300 μ L/ pipe	2 pipe/boxes	Colourless transparent liquid
				The justice hybridization solution	10 μ L/pipe	1 pipe/box	Colourless transparent liquid
The antisense hybridization solution	10 μ L/pipe	1 pipe/box	Colourless transparent liquid
				Confining liquid	1000 μ L/pipe	1 pipe/box	Colourless transparent liquid
The alkalinephosphatase enzyme antibody	1 μ L/pipe	1 pipe/box	Colourless transparent liquid
				Developer A	175 μ L/pipe	1 pipe/box	Yellow liquid
Developer B	320 μ L/pipe	1 pipe/box	Colourless transparent liquid
				The damping fluid I	The 90mL/bottle	1 bottle/box	Light yellow or colourless transparent liquid
The damping fluid II	The 80mL/bottle	1 bottle/box	Light yellow or colourless transparent liquid
				The damping fluid III	The 20mL/ bottle	3 bottle/boxes	Light yellow or colourless transparent liquid
The damping fluid IV	The 90mL/bottle	1 bottle/box	Light yellow or colourless transparent liquid
				Stationary liquid	The 90mL/bottle	1 bottle/box	Colourless transparent liquid
The positive control sample	6/box

The reagent preparation working concentration

1). 10 * damping fluid I is diluted to 1 * damping fluid I with tri-distilled water by 1:10;

2). 20 * damping fluid II is diluted to 2 * damping fluid II with tri-distilled water by 1:10;

Be diluted to 0.2 * damping fluid II by 1:100; Be diluted to 0.1 * damping fluid II by 1:200;

3). 10 * damping fluid III is diluted to 1 * damping fluid III with tri-distilled water by 1:10;

4) .10 * damping fluid IV with tri-distilled water by 1:10 be diluted to * the damping fluid IV (get 1#, 2#, each 10mL of 3#, add water to 100mL both can).

Embodiment 2

Use the implementation process of nucleic acid hybridization in situ detection method to each group blood preparation MICRORNA-330 expression amount:

1). get two of samples to be measured;

2). in glass jar, add Digestive system (Digestive system 100 μ L add 1 * damping fluid I 99.9ml, are working concentration) 50 ml, 37 ℃ of water-bath preheating 10min put 16 slides into, handle 12 min,use 1 * damping fluid I to wash 5min again for 37 ℃;

3). (protection liquid 1ml adds 1 * damping fluid

to the protection liquid with 0.2%; 99ml is working concentration) wash 10min; Tri-distilled water is washed 5min (above process is all carried out at glass jar); Take out slide, let its seasoning;

4). slide is put into the box of preserving moisture, add prehybridization solution 25 μ L/ sheets (being added in the place of cell), covered, the lid box of tightly preserving moisture is placed in 42 ℃ of constant water bath box more than the 3h;

5). take out slide, discard deckglass, slide is put into glass jar, the ethanol with 70%, 90%, 95% is respectively washed 2min, takes out seasoning;

6). slide is put into the box of preserving moisture, and one adds just hybridization solution 25 μ L/ sheets, and another adds antisense hybridization solution 25 μ L/ sheets, and covered is covered the box of tightly preserving moisture, and is placed on 16-24h in 42 ℃ of constant water bath box;

7). take out slide, discard deckglass, slide is put into glass jar:

In 42 ℃ of constant water bath box, wash twice, each 15min with 2 * damping fluid II;

In 42 ℃ of constant water bath box, wash once each 15min with 0.2 * damping fluid II;

In 42 ℃ of constant water bath box, wash twice, each 15min with 0.1 * damping fluid II;

8). wash 30s with 1 * damping fluid III, take out slide, seasoning;

9). slide is put into the box of preserving moisture, add 0.5% confining liquid (the 1ml confining liquid adds5ml 1 * damping fluid III), 100 μ L/ sheets, cover the box of tightly preserving moisture, at room temperature act on 30min.(this step need not add deckglass);

10). take out slide, wash 30s with 1 * damping fluid III, seasoning;

11). slide is put into the box of preserving moisture; Add X-AP antibody (getting a pipe alkaline phosphatase enzyme antibody) 100 μ L/ sheets, cover the box of tightly preserving moisture and at room temperature act on 30min to wherein adding 1.8ml 1 * damping fluid III; Time can not be long, otherwise can produce false positive (this step need not add deckglass);

12). take out slide, wash 3 times, each 15min with 1 * damping fluid III;

13). wash 2min with 1 * damping fluid IV, add developer (developer A73.3 μ L, developer B157.5 μ L is added in30mL 1 * damping fluid IV, mixing), room temperature lucifuge 16h is to more than the 18h;

14). wash 5min with tri-distilled water, seasoning, (add with glycerine 10% 1 * damping fluid I mixing) mounting microscopy.

Nucleic acid hybridization in situ detection method of the present invention is used digoxigenin labeled with goal gene; Become the RNA nucleic probe; The RNA nucleic acid to be measured of probe and human leukocytes is hybridized,, therefore under light microscopic, observe existence and the location of RNA again with the method colour developing of immunohistochemical methods; According to painted cell count, judge the expression amount of purpose RNA.

Lung cancer patient 20 examples, high risk population (length of smoking is more than 20 years) 20 examples, 20 of normal control groups.Take out all people's to be checked peripheral blood 3-5 milliliter (separation white corpuscle) and do in situ hybridization.The result representes that all cancer patients MICRORNA-330 expression amounts are low, and cell dyeing is shallow; The high risk population expresses slightly and reduces, decimal dyeing; Normal control group MICRORNA-330 expression amount is high, the dyeing of cell great majority, and concrete outcome is seen Fig. 2, Fig. 3, Fig. 4.

The lung cancer number	Expression amount %	Length of smoking is number more than 20 years	Expression amount %	Normal number	Expression amount %
						1	0	1	22	1	76
2	0	2	23	2	72
						3	0	3	16	3	77
4	0	4	20	4	86
						5	2	5	18	5	70
6	0	6	14	6	80
						7	0	7	28	7	69
8	0	8	26	8	67
						9	0	9	17	9	76
10	2	10	14	10	68
						11	0	11	23	11	76
12	0	12	25	12	80
						13	0	13	24	13	76
14	3	14	22	14	86
						15	0	15	19	15	82
16	0	16	16	16	79
						17	0	17	24	17	74
18	0	18	20	18	78
						19	0	19	23	19	82
20	2	20	17	20	80

。

1 ctttggcgat cactgcctct ctgggcctgt gtcttaggct ctgcaagatc aaccgagcaa

61 agcacacggc ctgcagagag gcagcgctct gccc

Claims (10)

1. a hybridization in situ detection kit comprises hybridization probe and affinity tag, it is characterized in that, described hybridization probe is the complementary sequence of sequence shown in the sequence table SEQ ID NO.1.

2. test kit as claimed in claim 1 is characterized in that, described affinity tag is selected from radioactive substance, chemoluminescence or substance that show color, vitamin H, metal king crab, resorcinolphthalein, enzyme and nano material.

3. test kit as claimed in claim 1 is characterized in that this test kit also comprises hybridization solution.

4. test kit as claimed in claim 1 is characterized in that this test kit also comprises synergistic agent.

5. test kit as claimed in claim 1 is characterized in that this test kit also comprises developer.

6. microRNA-330 gene hybridization in situ detection method is characterized in that this method may further comprise the steps:

(1) can form under the condition of stablizing hybridization complex at described hybridization probe of claim 1 and target sequence, RNA to be measured in the substrate is contacted with hybridization probe, form hybridization complex; With

(2) detect said hybridization complex.

7. detection method as claimed in claim 6 is characterized in that, the described condition of stablizing hybridization complex that forms is: the temperature of nucleic acid hybridization is 42 ℃; The time of nucleic acid hybridization is 16-24 hour.

8. detection method as claimed in claim 6 is characterized in that, described substrate is selected people's blood leucocyte sample for use.

9. detection method as claimed in claim 8 is characterized in that, described blood leucocyte sample is selected from cancer, high risk population, normal people's sample.

10.microRNA-330 gene detects cancer pathology in preparation and develops the application in the in situ hybridization test kit, it is characterized in that said test kit contains the described hybridization probe of claim 1.

Images